| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pneumococcal Infections | 14 | 2019 | 562 | 3.78 | Why? |
| Streptococcus pneumoniae | 13 | 2019 | 827 | 2.92 | Why? |
| Pneumococcal Vaccines | 10 | 2019 | 571 | 2.53 | Why? |
| Vaccines | 13 | 2021 | 3692 | 2.33 | Why? |
| Drug Resistance, Microbial | 6 | 2018 | 419 | 1.90 | Why? |
| Antigens, Bacterial | 3 | 2017 | 330 | 1.16 | Why? |
| Drug Resistance, Bacterial | 3 | 2019 | 1414 | 1.10 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 3 | 2018 | 64 | 1.04 | Why? |
| Anti-Bacterial Agents | 10 | 2019 | 10083 | 0.99 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2021 | 10649 | 0.97 | Why? |
| Vaccines, Conjugate | 4 | 2019 | 328 | 0.94 | Why? |
| Neisseria gonorrhoeae | 3 | 2018 | 142 | 0.92 | Why? |
| Research Design | 7 | 2021 | 5830 | 0.91 | Why? |
| Epidemiologic Studies | 2 | 2020 | 554 | 0.85 | Why? |
| Serogroup | 5 | 2018 | 510 | 0.85 | Why? |
| Communicable Diseases, Emerging | 4 | 2018 | 2523 | 0.81 | Why? |
| Carrier State | 5 | 2019 | 2100 | 0.80 | Why? |
| Bacterial Vaccines | 2 | 2018 | 139 | 0.80 | Why? |
| Influenza A virus | 3 | 2018 | 2234 | 0.78 | Why? |
| Bacteria | 3 | 2019 | 1897 | 0.77 | Why? |
| Clinical Trials as Topic | 6 | 2021 | 7330 | 0.76 | Why? |
| Antibodies, Bacterial | 3 | 2017 | 510 | 0.75 | Why? |
| Microbiota | 2 | 2018 | 1240 | 0.72 | Why? |
| Immunity, Herd | 4 | 2021 | 1011 | 0.71 | Why? |
| Viral Vaccines | 5 | 2020 | 7560 | 0.70 | Why? |
| Toxins, Biological | 1 | 2017 | 40 | 0.69 | Why? |
| Gonorrhea | 2 | 2018 | 315 | 0.69 | Why? |
| Epidemiologic Research Design | 1 | 2018 | 166 | 0.64 | Why? |
| Off-Label Use | 1 | 2021 | 553 | 0.63 | Why? |
| Models, Immunological | 2 | 2019 | 727 | 0.62 | Why? |
| Coronaviridae Infections | 1 | 2020 | 442 | 0.62 | Why? |
| Observational Studies as Topic | 2 | 2021 | 1887 | 0.62 | Why? |
| Epidemiologic Methods | 1 | 2020 | 392 | 0.61 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.61 | Why? |
| Biomedical Research | 4 | 2018 | 5270 | 0.59 | Why? |
| Drugs, Investigational | 1 | 2018 | 198 | 0.59 | Why? |
| Bias | 4 | 2021 | 1109 | 0.57 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.55 | Why? |
| Models, Statistical | 5 | 2021 | 5312 | 0.55 | Why? |
| Science | 1 | 2020 | 463 | 0.51 | Why? |
| Vaccination | 11 | 2021 | 19050 | 0.50 | Why? |
| Disease Outbreaks | 12 | 2020 | 27595 | 0.49 | Why? |
| Models, Biological | 3 | 2020 | 4907 | 0.49 | Why? |
| Interprofessional Relations | 1 | 2020 | 1013 | 0.48 | Why? |
| Respiration Disorders | 1 | 2018 | 526 | 0.48 | Why? |
| Sentinel Surveillance | 1 | 2020 | 1093 | 0.48 | Why? |
| Influenza, Human | 8 | 2021 | 10779 | 0.47 | Why? |
| Hospital Bed Capacity | 1 | 2020 | 1300 | 0.47 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.46 | Why? |
| Sexual Partners | 1 | 2017 | 612 | 0.46 | Why? |
| Pandemics | 31 | 2021 | 389249 | 0.46 | Why? |
| Drug Prescriptions | 2 | 2019 | 1062 | 0.45 | Why? |
| Seroepidemiologic Studies | 4 | 2021 | 10017 | 0.44 | Why? |
| Epidemics | 4 | 2020 | 6407 | 0.43 | Why? |
| Computer Simulation | 4 | 2021 | 4982 | 0.43 | Why? |
| Pneumonia, Viral | 22 | 2020 | 243684 | 0.43 | Why? |
| Respiratory Syncytial Virus Infections | 2 | 2018 | 1234 | 0.42 | Why? |
| Coronavirus Infections | 21 | 2020 | 253789 | 0.41 | Why? |
| Betacoronavirus | 19 | 2020 | 204454 | 0.40 | Why? |
| Humans | 88 | 2021 | 930598 | 0.39 | Why? |
| Disease Transmission, Infectious | 4 | 2020 | 9044 | 0.38 | Why? |
| Influenza Vaccines | 4 | 2018 | 2941 | 0.36 | Why? |
| Bacterial Infections | 2 | 2019 | 2229 | 0.36 | Why? |
| Age Factors | 7 | 2021 | 21039 | 0.35 | Why? |
| Publishing | 1 | 2018 | 990 | 0.35 | Why? |
| Evidence-Based Medicine | 2 | 2020 | 3228 | 0.35 | Why? |
| Schools | 2 | 2021 | 4187 | 0.35 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.34 | Why? |
| Drug Resistance, Viral | 2 | 2013 | 1083 | 0.33 | Why? |
| Travel | 3 | 2021 | 7220 | 0.33 | Why? |
| Virus Diseases | 2 | 2015 | 3779 | 0.33 | Why? |
| Otitis Media | 2 | 2018 | 106 | 0.33 | Why? |
| Selection, Genetic | 4 | 2018 | 691 | 0.33 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.32 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2009 | 2984 | 0.32 | Why? |
| Placebos | 2 | 2021 | 629 | 0.32 | Why? |
| Staphylococcal Infections | 2 | 2013 | 1099 | 0.32 | Why? |
| Ebola Vaccines | 2 | 2018 | 126 | 0.32 | Why? |
| Hemorrhagic Fever, Ebola | 4 | 2018 | 1475 | 0.31 | Why? |
| Health Status Disparities | 2 | 2021 | 4072 | 0.31 | Why? |
| Coronavirus | 5 | 2020 | 18339 | 0.29 | Why? |
| Host-Pathogen Interactions | 4 | 2018 | 11041 | 0.29 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.29 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.29 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2013 | 1115 | 0.29 | Why? |
| Ethics, Research | 2 | 2018 | 328 | 0.28 | Why? |
| Models, Theoretical | 5 | 2021 | 6659 | 0.28 | Why? |
| Disaster Planning | 1 | 2017 | 1680 | 0.27 | Why? |
| Computational Biology | 2 | 2020 | 4514 | 0.27 | Why? |
| Bacterial Proteins | 3 | 2017 | 1318 | 0.27 | Why? |
| Staphylococcus aureus | 3 | 2018 | 844 | 0.26 | Why? |
| Immunogenicity, Vaccine | 3 | 2021 | 4624 | 0.26 | Why? |
| Databases, Factual | 2 | 2021 | 6248 | 0.26 | Why? |
| Prevalence | 8 | 2021 | 25773 | 0.25 | Why? |
| Adolescent | 16 | 2021 | 86841 | 0.25 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2015 | 8843 | 0.25 | Why? |
| Ambulatory Care | 1 | 2019 | 4947 | 0.23 | Why? |
| United States | 11 | 2021 | 46150 | 0.23 | Why? |
| Public Health Surveillance | 3 | 2021 | 3129 | 0.23 | Why? |
| Communication | 1 | 2019 | 5206 | 0.22 | Why? |
| Epistasis, Genetic | 2 | 2018 | 35 | 0.22 | Why? |
| Research | 3 | 2018 | 2115 | 0.22 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.22 | Why? |
| SARS Virus | 2 | 2015 | 13021 | 0.22 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.21 | Why? |
| Child, Preschool | 9 | 2020 | 36283 | 0.21 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.21 | Why? |
| Mass Vaccination | 2 | 2021 | 1101 | 0.21 | Why? |
| Incidence | 10 | 2021 | 25622 | 0.21 | Why? |
| Containment of Biohazards | 2 | 2018 | 762 | 0.20 | Why? |
| Bayes Theorem | 4 | 2021 | 3237 | 0.20 | Why? |
| Child | 12 | 2021 | 70012 | 0.20 | Why? |
| Population Surveillance | 4 | 2021 | 4967 | 0.20 | Why? |
| Sample Size | 2 | 2019 | 518 | 0.20 | Why? |
| Communicable Disease Control | 4 | 2020 | 29620 | 0.20 | Why? |
| Women, Working | 1 | 2020 | 96 | 0.19 | Why? |
| Social Welfare | 1 | 2020 | 141 | 0.19 | Why? |
| Communicable Diseases | 3 | 2018 | 2148 | 0.19 | Why? |
| Adult | 21 | 2021 | 244371 | 0.18 | Why? |
| Global Health | 3 | 2018 | 13911 | 0.18 | Why? |
| Infant | 8 | 2020 | 30274 | 0.18 | Why? |
| Serotyping | 1 | 2018 | 154 | 0.18 | Why? |
| Gain of Function Mutation | 1 | 2018 | 54 | 0.18 | Why? |
| Cities | 2 | 2021 | 4937 | 0.18 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.18 | Why? |
| Genetics, Population | 1 | 2018 | 162 | 0.17 | Why? |
| Biological Evolution | 2 | 2021 | 641 | 0.17 | Why? |
| Mammals | 1 | 2020 | 315 | 0.17 | Why? |
| Adhesins, Bacterial | 1 | 2017 | 39 | 0.17 | Why? |
| Population Dynamics | 2 | 2018 | 378 | 0.17 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2019 | 593 | 0.17 | Why? |
| Beneficence | 1 | 2017 | 62 | 0.17 | Why? |
| Parasites | 1 | 1997 | 39 | 0.17 | Why? |
| Penicillins | 1 | 2018 | 132 | 0.17 | Why? |
| Adaptation, Biological | 1 | 2018 | 179 | 0.16 | Why? |
| Health Services Research | 2 | 2020 | 756 | 0.16 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.16 | Why? |
| Nasopharynx | 5 | 2018 | 10224 | 0.16 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.15 | Why? |
| School Teachers | 1 | 2020 | 345 | 0.15 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.15 | Why? |
| Parasitic Diseases | 1 | 1997 | 84 | 0.15 | Why? |
| Morals | 1 | 2021 | 483 | 0.15 | Why? |
| Peer Review | 1 | 2018 | 204 | 0.15 | Why? |
| Codon | 1 | 2017 | 287 | 0.15 | Why? |
| Adaptive Immunity | 2 | 2020 | 2585 | 0.15 | Why? |
| Data Interpretation, Statistical | 1 | 2020 | 657 | 0.15 | Why? |
| Membrane Transport Proteins | 1 | 2017 | 152 | 0.15 | Why? |
| China | 7 | 2021 | 50654 | 0.15 | Why? |
| Microbial Sensitivity Tests | 3 | 2018 | 2886 | 0.15 | Why? |
| Capital Financing | 1 | 2014 | 35 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2018 | 284 | 0.14 | Why? |
| Catheter-Related Infections | 1 | 2019 | 381 | 0.14 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.14 | Why? |
| Species Specificity | 1 | 2018 | 1356 | 0.14 | Why? |
| Models, Genetic | 1 | 2017 | 434 | 0.14 | Why? |
| Rhinovirus | 1 | 2020 | 979 | 0.14 | Why? |
| DNA | 1 | 2020 | 778 | 0.13 | Why? |
| Heat-Shock Proteins | 1 | 2017 | 226 | 0.13 | Why? |
| Coronaviridae | 1 | 2020 | 923 | 0.13 | Why? |
| Zika Virus Infection | 2 | 2018 | 1920 | 0.13 | Why? |
| Antibody Formation | 2 | 2017 | 4038 | 0.13 | Why? |
| Linear Models | 1 | 2020 | 1914 | 0.13 | Why? |
| Age Distribution | 2 | 2020 | 3567 | 0.13 | Why? |
| Virulence | 2 | 2018 | 2172 | 0.13 | Why? |
| Bioethics | 1 | 2018 | 253 | 0.13 | Why? |
| Urinary Tract Infections | 1 | 2019 | 534 | 0.12 | Why? |
| New York | 1 | 2021 | 2488 | 0.12 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.12 | Why? |
| Safety | 1 | 2021 | 1583 | 0.12 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.12 | Why? |
| RNA | 1 | 2020 | 1278 | 0.12 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2017 | 572 | 0.12 | Why? |
| Health Priorities | 1 | 2021 | 959 | 0.12 | Why? |
| Coronavirus OC43, Human | 1 | 2020 | 1157 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.11 | Why? |
| Genetic Variation | 2 | 2017 | 3919 | 0.11 | Why? |
| Israel | 4 | 2021 | 2751 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.11 | Why? |
| Aged | 14 | 2021 | 215776 | 0.11 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
| Middle Aged | 14 | 2021 | 270681 | 0.11 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.11 | Why? |
| Recombination, Genetic | 1 | 2018 | 1265 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.10 | Why? |
| Minority Groups | 1 | 2021 | 1631 | 0.10 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.10 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.10 | Why? |
| Cost of Illness | 1 | 2021 | 1903 | 0.10 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.10 | Why? |
| Family Characteristics | 1 | 2021 | 2551 | 0.10 | Why? |
| Singapore | 1 | 2020 | 3641 | 0.10 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.10 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.09 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.09 | Why? |
| Licensure | 2 | 2020 | 144 | 0.09 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.09 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.09 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Immunization | 1 | 2017 | 2019 | 0.09 | Why? |
| Female | 15 | 2021 | 380317 | 0.09 | Why? |
| Genomics | 2 | 2017 | 3118 | 0.09 | Why? |
| Wisconsin | 1 | 2009 | 607 | 0.09 | Why? |
| Seasons | 1 | 2020 | 4071 | 0.08 | Why? |
| Vaccines, Subunit | 1 | 2013 | 1088 | 0.08 | Why? |
| Linkage Disequilibrium | 2 | 2018 | 191 | 0.08 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2014 | 846 | 0.08 | Why? |
| Animals | 5 | 2021 | 78931 | 0.08 | Why? |
| South Africa | 1 | 2017 | 3326 | 0.08 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.08 | Why? |
| Uncertainty | 1 | 2017 | 1888 | 0.08 | Why? |
| Immunization Programs | 1 | 2018 | 2006 | 0.08 | Why? |
| African Americans | 1 | 2021 | 3363 | 0.07 | Why? |
| Probability | 1 | 2009 | 923 | 0.07 | Why? |
| Myocarditis | 1 | 2021 | 2731 | 0.07 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.07 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.07 | Why? |
| Health Policy | 3 | 2020 | 6242 | 0.07 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 711 | 0.07 | Why? |
| Orthomyxoviridae | 1 | 2013 | 1168 | 0.07 | Why? |
| Germany | 1 | 2020 | 9196 | 0.07 | Why? |
| Epitopes | 1 | 2017 | 4113 | 0.07 | Why? |
| Male | 13 | 2021 | 367725 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.07 | Why? |
| Immunoglobulin G | 2 | 2017 | 21571 | 0.06 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| New York City | 2 | 2021 | 7432 | 0.06 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3633 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Kaplan-Meier Estimate | 2 | 2021 | 4260 | 0.06 | Why? |
| Biohazard Release | 1 | 2021 | 54 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.05 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Voluntary Programs | 1 | 2020 | 22 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Clavulanic Acid | 1 | 2018 | 20 | 0.05 | Why? |
| Occupational Diseases | 1 | 2014 | 2787 | 0.05 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.05 | Why? |
| Insurance | 1 | 2018 | 37 | 0.05 | Why? |
| International Classification of Diseases | 1 | 2021 | 265 | 0.05 | Why? |
| Occupational Health | 1 | 2014 | 3965 | 0.04 | Why? |
| Resource Allocation | 1 | 2009 | 1771 | 0.04 | Why? |
| Amoxicillin | 1 | 2018 | 98 | 0.04 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.04 | Why? |
| World Health Organization | 2 | 2021 | 4213 | 0.04 | Why? |
| Asymptomatic Diseases | 2 | 2021 | 3444 | 0.04 | Why? |
| Self-Control | 1 | 2018 | 73 | 0.04 | Why? |
| Epidemiological Monitoring | 2 | 2021 | 3493 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2020 | 48226 | 0.04 | Why? |
| Risk | 2 | 2021 | 5288 | 0.04 | Why? |
| Monte Carlo Method | 1 | 2020 | 577 | 0.04 | Why? |
| Immunocompromised Host | 1 | 2014 | 5150 | 0.04 | Why? |
| Sierra Leone | 1 | 2017 | 267 | 0.04 | Why? |
| Virology | 1 | 2021 | 489 | 0.04 | Why? |
| Mathematics | 1 | 1997 | 65 | 0.04 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Aircraft | 1 | 2021 | 498 | 0.04 | Why? |
| Host-Parasite Interactions | 1 | 1997 | 112 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.04 | Why? |
| Quantitative Trait Loci | 1 | 2018 | 340 | 0.04 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.04 | Why? |
| Herpes Zoster | 1 | 2021 | 331 | 0.04 | Why? |
| Antigens, Viral | 1 | 2013 | 6298 | 0.04 | Why? |
| Lymphadenopathy | 1 | 2021 | 444 | 0.04 | Why? |
| Viral Proteins | 1 | 2014 | 7370 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| Arabs | 1 | 2017 | 298 | 0.03 | Why? |
| Privacy | 1 | 2020 | 636 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2020 | 1182 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Massachusetts | 1 | 2017 | 1279 | 0.03 | Why? |
| Methicillin | 1 | 2011 | 73 | 0.03 | Why? |
| Africa | 1 | 2021 | 2986 | 0.03 | Why? |
| Methicillin Resistance | 1 | 2011 | 77 | 0.03 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.03 | Why? |
| Appendicitis | 1 | 2021 | 946 | 0.03 | Why? |
| Sequence Homology, Amino Acid | 1 | 2014 | 945 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Medicare | 1 | 2018 | 1048 | 0.03 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.02 | Why? |
| Health Equity | 1 | 2021 | 1223 | 0.02 | Why? |
| Attitude | 1 | 2018 | 1481 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2014 | 3198 | 0.02 | Why? |
| Research Personnel | 1 | 2018 | 1037 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Neuraminidase | 1 | 2009 | 289 | 0.02 | Why? |
| Antiviral Agents | 2 | 2009 | 41703 | 0.02 | Why? |
| England | 1 | 2018 | 5116 | 0.02 | Why? |
| Patient Selection | 1 | 2021 | 4560 | 0.02 | Why? |
| Critical Care | 1 | 2009 | 14081 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Europe | 1 | 2020 | 12702 | 0.02 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.02 | Why? |
| Azithromycin | 1 | 2018 | 3943 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2014 | 6049 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Community-Acquired Infections | 1 | 2011 | 2328 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Australia | 1 | 2009 | 6306 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Genome, Viral | 1 | 2014 | 13157 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |